Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NiproTSE:8086 +0.39%70 OCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates TSE:8086 with a GF Score™ of 70/100 and a GF Value™ of 円1,457.04 (Fairly Valued). The stock has 6 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Nipro ranks better than 54.53% on this metric.
OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Nipro's Cash Flow from Operations for the
three
months ended in Mar. 2026 was 円0 Mil. Nipro's Revenue for the
three
months ended in Mar. 2026 was 円173,233 Mil. Therefore, Nipro's OCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.
The historical rank and industry rank for Nipro's OCF Margin % or its related term are showing as below:
TSE:8086'
s OCF Margin % Range Over the Past 10 Years
Min: 1.91 Med: 10.04 Max: 14.51
Current: 8.27
During the past 13 years, the highest OCF Margin % of Nipro was 14.51%. The lowest was 1.91%. And the median was 10.04%.
TSE:8086's OCF Margin % is ranked better than 54.53% of 816
companies
in the Medical Devices & Instruments industry
Industry Median: 5.785
vs TSE:8086: 8.27
Nipro OCF Margin % Related Terms
Nipro OCF Margin % Historical Data
* Premium members only.
The historical data trend for Nipro's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:8086 vs ISRG, BDX, MDLN: OCF Margin % Comparison
For the Medical Instruments & Supplies subindustry, Nipro's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nipro OCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nipro's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Nipro's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nipro (TSE:8086) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Nipro and its competitors. Over the past decade, Nipro's OCF Margin % has ranged from 1.91 to 14.51. According to the industry distribution chart, Nipro ranks #371 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 45.5%.
Is Nipro's OCF Margin % too high?
Nipro's current OCF Margin % is 0.00%. Over the past 10 years, this metric has ranged from a low of 1.91 to a high of 14.51. Based on the distribution chart, Nipro ranks #371 out of 816 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Nipro has a GF Score™ of 70/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Nipro's OCF Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Nipro ranks #371 out of 816 companies for OCF Margin %. This puts Nipro in the upper half of its industry. The industry median OCF Margin % is 5.79. Historically, Nipro's own OCF Margin % has ranged from 1.91 to 14.51 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Medical Devices & Instruments company?
The median OCF Margin % among Medical Devices & Instruments companies is 5.79, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Nipro and its competitors. For the Medical Devices & Instruments industry, the median OCF Margin % is 5.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nipro's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nipro stock overvalued right now?
Based on GuruFocus' analysis, Nipro (TSE:8086) is currently considered Fairly Valued. The stock's GF Value™ is 円1,457.04, compared to a current price of 円1,552.50 — trading 6.6% above its estimated fair value. The current OCF Margin % is 0.00%. Nipro's overall GF Score™ is 70/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Nipro (TSE:8086), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nipro (TSE:8086) Overvalued in 2026?
Based on GuruFocus' analysis, Nipro stock appears to be overvalued.
The current stock price of 円1,552.50 is trading 6.6% above its estimated GF Value™ of 円1,457.04.
GuruFocus considers Nipro to be Fairly Valued.
Key valuation signals for TSE:8086:
OCF Margin %: 0.00%
GF Value™: 円1,457.04 vs. price of 円1,552.50 (6.6% above fair value)
No single metric tells the full story. See the TSE:8086 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nipro Corp develops medical devices, most of which are related to dialysis and artificial organs. The firm operates in four segments: medical, pharmaceutical, glass, and other. The medical segment contributes the majority of revenue. It sells products related to injections, infusions, artificial organs, and cell cultures, as well as medical equipment for renal treatment, diabetes, and generic drugs. Renal products contribute the largest proportion of sales within the medical segment. The pharmaceutical segment manufactures pharmaceuticals, including oral drugs and injectables, which are supplied to pharmaceutical companies in Japan. The glass business sells glass products used for medical applications, such as vials and syringes. Nipro generates the majority of its revenue in Japan.
70GF Score
Get the complete analysis for TSE:8086
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:8086 has been successfully added to your 
